We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

  • The tiny eye implant is composed of a single layer of human embryonic stem cells that mimics normal tissue.
  • USC Roski Eye Institute
  • Rewriting Life

    This stem-cell implant could halt an incredibly common cause of blindness

    The dream of a stem-cell revolution hasn’t yet materialized—but a small study appears to have used the technology to ward off macular degeneration.

    An eye implant made of a thin sheet of human embryonic stem cells might be an effective treatment for a common form of vision loss.

    Researchers at the University of Southern California grew stem-cell membranes in a sterile lab for a month and then inserted them into the eyes of four people with “dry” macular degeneration, the leading cause of blindness in developed countries. An estimated 196 million people worldwide will have some form of macular degeneration by 2020.

    People with the dry type suffer from a progressive thinning of the retinal pigment epithelium, a layer of cells that support and nourish the light-sensing photoreceptors. Without this vital layer, which the implant is intended to replace, the photoreceptor cells also die off, and people slowly lose their eyesight.

    Researchers monitored the four patients over the course of a year, and found that their eyesight didn’t decline.

    The study was meant to test the safety of the implant, so only patients with very advanced macular degeneration were included. Because of that, study author Amir Kashani says, he didn’t expect an improvement in vision. “But after surgery, one patient could read 17 more letters on an eye chart than before surgery,” he says. 

    Two patients were also able to focus their gaze better than before. The results appear today in the journal Science Translational Medicine. Kashani thinks the implant will be more effective for people in earlier stages of the disease.

    When stem cells were first extracted from human embryos 20 years ago, scientists marveled at their ability to change into any type of cell in the body and thought they would soon be used to treat all types of diseases, from eye disorders to diabetes. But that dream has yet to be realized. There are no embryonic stem-cell treatments approved by the US Food and Drug Administration, and most human studies of such therapies have shown unremarkable results.

    Researchers have, for example, tried injecting embryonic stem cells directly into the eye, but the cells moved around in the eye and weren’t very effective. “The reason we’re encouraged is that we’re replacing the exact anatomical defect that is causing the disease,” Kashani says.

    Another research team, at Moorfields Eye Hospital in London, recently reported that a similar stem-cell patch they developed was able to restore sight in two patients with the wet form of macular degeneration, which is caused by abnormal blood vessels that leak into the central part of the retina.

    But both studies were small and neither had control groups, so it’s hard to know whether the perceived benefits can actually be credited to the stem-cell therapies.

    Paul Knoepfler, a stem-cell biologist at the University of California, Davis, says work on stem-cell therapies has been slow because of the tremendous safety risks involved. “We’ve seen what can go horribly wrong with shortcuts with stem cells by for-profit clinics,” he says.

    Last year, for example, the FDA vowed to crack down on spurious clinics that blinded patients with eye injections of stem cells derived from people’s fat.

    Tech Obsessive?
    Become an Insider to get the story behind the story — and before anyone else.

    Subscribe today
    More from Rewriting Life

    Reprogramming our bodies to make us healthier.

    Want more award-winning journalism? Subscribe to Insider Plus.
    • Insider Plus {! insider.prices.plus !}*

      {! insider.display.menuOptionsLabel !}

      Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

      See details+

      Print + Digital Magazine (6 bi-monthly issues)

      Unlimited online access including all articles, multimedia, and more

      The Download newsletter with top tech stories delivered daily to your inbox

      Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

      10% Discount to MIT Technology Review events and MIT Press

      Ad-free website experience

    You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.